myStoria secures $1.6 million in seed funding, with Graphite Ventures leading the round.

      The Ontario startup merges AI technology with skilled human professionals to assist patients dealing with PCOS, endometriosis, fertility issues, and perimenopause—conditions known for their extensive diagnostic delays and disjointed care in the healthcare system. Graphite Ventures spearheaded the funding round.

      When patients receive referrals to specialists, confusing test results, or diagnoses that appear in their online portals before being discussed by their doctors, the healthcare system effectively burdens them with an additional responsibility. They must assume the roles of project manager, medical historian, insurance coordinator, and advocate, all without proper training, tools, or support. myStoria aims to create the necessary framework for these individuals.

      The startup has secured $1.625 million in a seed funding round led by Graphite Ventures, with additional contributions from Conexus Venture Capital, Adrenaline Fund, Phoenix Fire Fund, and a collective of strategic angel investors.

      The company originated in the area of reproductive health with a focus on fertility and IVF, which are known for having high dismissal rates, significant diagnostic delays, and fragmented treatment pathways compared to other medical fields. Founder and CEO Jessica Chalk spent six years navigating her own infertility challenges, undergoing multiple treatments that cost her over $100,000, before building the platform she felt was lacking.

      This seed round broadens myStoria’s focus to encompass the entire reproductive health lifecycle: it will address PCOS, endometriosis, perimenopause, and hormonal health, each with tailored pathways for specific conditions.

      The platform integrates AI with trained professionals in a human-in-the-loop model. Central to it is a “Context Engine”, a proprietary component that organizes a user’s complete health information, including documents, audio files, photos, symptoms, and appointment records, into a structured format optimized for AI interpretation.

      Every interaction builds upon this cumulative history. Qualified professionals review the AI-generated insights and provide clinical context. The goal is to deliver personalized and accurate responses that consider the entire health picture rather than generic information.

      The platform will be available on iOS and Android through a freemium model.

      Aaron Bast, GP at Graphite Ventures, framed the investment as an infrastructure development; myStoria is “not just another consumer app,” but a “defensible infrastructure play” that maintains ownership of the patient’s longitudinal health data. Graphite, which targets seed-stage B2B and digital health firms in Canada, typically invests between $500K and $1.5M.

      This funding round for myStoria sits at the higher end of that spectrum, including a broader syndicate. Alex Shimla, Principal at Conexus Venture Capital, referred to the company as “creating the patient-owned infrastructure that the system has been lacking.”

      The long-term vision is intentionally broad, not limited to any specific condition; reproductive health serves as the entry point into a model that could eventually assist patients managing cancer, heart diseases, autoimmune disorders, or any complex care scenario where the patient must act as their own care coordinator.